Review of treatment management for patients with Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer
Introduction: Nowadays, lung cancer is the most popular cause of cancer-related deaths all around the world. However, the new progressions in determining specific oncogenes with driver mutations, such as the Epidermal Growth Factor Receptor (EGFR) gene has ameliorated the prognosis of non-small-cell lung cancer formation. Studies on these bio-markers have targeted the pathways in which drugs act as specific inhibitors to cancer progression. Tyrosine Kinase Inhibitors (TKIs) against EGFR, such as Erlotinib and Gefitinib, have been able to provide considerable progression free survival (PFS) for patients by stopping these tumour boosting properties in non-small-cell lung cancers. Unfortunately, persistent resistance mechanisms have made these agents ineffective in their treatment. To overcome resistance, new multiple agents were developed, but the treat of resistance still looms over each new advance in EGFR inhibition based targeted therapy. This article reviews the 1st and 2nd Generation EGFR inhibition, common resistance mechanisms, 3rd Generation EGFR inhibitor and subsequent treatment option.
Contact SPER Publications
SPER Publications and Solutions Pvt. Ltd.
HD - 236,
Near The Shri Ram Millenium School,
Noida-Greater Noida Expressway,
Noida-201301 [Delhi-NCR] India